Understand the source comparison
How Does the GLP-1 Class Compare? (Comparison Table)
The table below summarizes the major agents by mechanism, route, typical efficacy, and regulatory status. Efficacy figures are drawn from pivotal trials and are approximate; individual results vary widely and depend on dose, duration, and adherence. Exenatide
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below summarizes the major agents by mechanism, route, typical efficacy, and regulatory status. Efficacy figures are drawn from pivotal trials and are approximate; individual results vary widely and depend on dose, duration, and adherence.
- Exenatide
- GLP-1
- SC, twice daily or weekly
- Modest
- Approved (T2D)
- Lixisenatide
- SC, once daily
- Liraglutide
- ~5–8%
- Approved (T2D & obesity)
- Dulaglutide
- SC, once weekly
- Semaglutide (injectable)
- ~15%
- Semaglutide (oral)
- Oral, once daily
- Moderate–high
- Approved
- Tirzepatide
- GIP + GLP-1
- ~20%+
- Orforglipron (Foundayo)
- GLP-1 (small molecule)
- High
- Approved (obesity, 2026); T2D under review
- Retatrutide
- GIP + GLP-1 + glucagon
- Very high (investigational)
- Investigational (Phase 3)